{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=2",
    "query": {
      "intervention": "azacitidine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T11:46:59.914Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00113321",
      "title": "Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 16,
      "start_date": "2005-03",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113321"
    },
    {
      "nct_id": "NCT00741234",
      "title": "A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Hematologic Malignancies",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "SB939",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "S*BIO",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2007-04",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-04-23",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00741234"
    },
    {
      "nct_id": "NCT06597734",
      "title": "A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia",
        "Advanced Myeloproliferative Neoplasms",
        "IDH1-mutated Higher-Risk Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Olutasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-01-28",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06597734"
    },
    {
      "nct_id": "NCT03306264",
      "title": "Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Chronic Myelomonocytic Leukemia",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "ASTX727",
          "type": "DRUG"
        },
        {
          "name": "Dacogen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 227,
      "start_date": "2018-02-15",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 39,
      "location_summary": "Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03306264"
    },
    {
      "nct_id": "NCT00042016",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "decitabine (5-aza-2'deoxycytidine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2002-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-10-14",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Escondido, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042016"
    },
    {
      "nct_id": "NCT04980404",
      "title": "Inqovi Maintenance Therapy in Myeloid Neoplasms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Chronic Myelomonocytic Leukemia",
        "Stem Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Inqovi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-09-17",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980404"
    },
    {
      "nct_id": "NCT01350947",
      "title": "A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "5-Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2011-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Portland, Oregon • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01350947"
    },
    {
      "nct_id": "NCT03066648",
      "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Leukemia, Myeloid",
        "Leukemia, Myeloid, Acute",
        "Myelodysplastic Syndromes",
        "Preleukemia",
        "Bone Marrow Diseases",
        "Hematologic Diseases",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        },
        {
          "name": "MBG453",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-07-06",
      "completion_date": "2023-09-08",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Portland, Oregon • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03066648"
    },
    {
      "nct_id": "NCT01522976",
      "title": "Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia",
        "Chronic Myelomonocytic Leukemia-1",
        "Chronic Myelomonocytic Leukemia-2",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Myelodysplastic Syndrome With Excess Blasts-1",
        "Myelodysplastic Syndrome/Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2012-03-01",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 280,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522976"
    },
    {
      "nct_id": "NCT01168219",
      "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Adult Acute Megakaryoblastic Leukemia",
        "Adult Acute Monoblastic Leukemia",
        "Adult Acute Monocytic Leukemia",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With Maturation",
        "Adult Acute Myeloid Leukemia With Minimal Differentiation",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1",
        "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL",
        "Adult Acute Myeloid Leukemia Without Maturation",
        "Adult Acute Myelomonocytic Leukemia",
        "Adult Erythroleukemia",
        "Adult Pure Erythroid Leukemia",
        "Alkylating Agent-Related Acute Myeloid Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 68,
      "start_date": "2010-07-15",
      "completion_date": "2020-02-01",
      "has_results": true,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-06-07T11:46:59.914Z",
      "location_count": 17,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168219"
    }
  ]
}